86 results about "Intestinal epithelium" patented technology

The present invention relates in general to methods and products for initiating an immune response against an antigen, and in particular relates to transepithelial delivery of antigens to provoke tolerance and immunity. The present invention further relates to methods and products for the transepithelial delivery of therapeutics. In particular, the invention relates to methods and compositions for the delivery of therapeutics conjugated to a FcRn binding partner to intestinal epithelium, mucosal epithelium and epithelium of the lung. The present invention further relates to the synthesis, preparation and use of the FcRn binding partner conjugates as, or in, pharmaceutical compositions for oral systemic delivery of drugs and vaccines.

The present invention relates in general to methods and products for initiating an immune response against an antigen, and in particular relates to transepithelial delivery of antigens to provoke tolerance and immunity. The present invention further relates to methods and products for the transepithelial delivery of therapeutics. In particular, the invention relates to methods and compositions for the delivery of therapeutics conjugated to a FcRn binding partner to intestinal epithelium, mucosal epithelium and epithelium of the lung. The present invention further relates to the synthesis, preparation and use of the FcRn binding partner conjugates as, or in, pharmaceutical compositions for oral systemic delivery of drugs and vaccines.

Methods are provided for long term culture of mammalian intestinal cells. Cultures are initiated with fragments of mammalian intestinal tissue, which are then maintained embedded in a gel substrate that provides an air-liquid interface. Intestinal epithelium in cultures of the invention can be continuously grown for extended periods of time. Mammalian intestinal cells cultured by the methods of the invention recapitulate features of intestinal growth in vivo.

Described are cell culture solutions and systems for epithelial stem cell and organoid cultures, formation of epithelial constructs and uses of the same in transplantation. A single layer of epithelial cells that actively self-renews and is organized into crypts and villi clothes the intestine. It has been recently shown that the renewal of intestinal epithelium is driven by Lgr5+ intestinal stem cells (ISC) that reside at the base of these crypts (Barker et al., 2007). Lgr5+ stem cells can be isolated and cultured in vitro to form organoids containing crypt-vcllus structures that recapitulates the native intestinal epithelium (Sato et al., 2009).

The present invention is directed to a particular arabinoxylan (“AX”) preparation and the finding that this preparation has a beneficial effect on the organization of the intestinal microbial community in the lumen and in particular at the site of the gut mucosa, where it modulates the barrier function of the intestinal surface, primarily by modulating the mucosa-associated microbial community towards a relative increase of health beneficial bacteria, such as bifidobacteria and lactobacilli. It is accordingly a first aspect of the present invention to provide said arabinoxylan preparation characterized in comprising isolated water-soluble arabinoxylans and the use thereof to improve functioning (e.g. barrier function) of the intestinal epithelium. Thus, in a further aspect the present invention provides compositions, both pharmaceutical and nutritional compositions, comprising said arabinoxylan preparations; in particular pharmaceuticals, medical foods, food supplements or food compositions, such as infant formula products, dairy products, bakery products or pastry products. The compositions optionally comprise probiotics such as Bifidobacterium or Lactobacillus.

The invention relates to the technical field of microorganisms, in particular to probiotic lactobacillus plantarum and application thereof in preparation of low-salt fermented meat food. The invention provides a strain of lactobacillus plantarum CMRC 19L, which is preserved in the China General Microbiological Culture Collection Center (CGMCC), and the preservation number is CGMCC No.11347. The lactobacillus plantarum CMRC 19L is high in growth speed, capable of inhibiting growth of pathogenic bacteria, excellent in meat fermentation performance, resistant to the gastrointestinal tract environment, high in adhesiveness to intestinal mucus protein and intestinal epithelioid cells and good in probiotic performance. As a leavening agent, the strain can ensure the edible safety and flavor quality of the low-salt fermented meat food, and significantly improve the nutritional value of the fermented meat food.

The invention discloses application of galanthamine in prevention and treatment for soybean meal-induced enteritis of fishes. According to a neuroregulation theory of intestinal mucosal immunity, in combination with two methods of disease modeling and biological information analysis, it is inferred that the galanthamine is a potential medicine for preventing and treating the soybean meal-induced enteritis; it is proved by an experiment that the galanthamine can activate expression of anti-inflammatory cytokines in intestinal tracts of bred fishes through addition into feed or intramuscular injection in backs, inhibit intestinal inflammations, maintain tight junctions of intestinal epithelium barriers, and inhibit intestinal epithelium apoptosis, therefore the enteritis caused by a soybeanmeal feed is relieved, recovery of growth of the fishes can be achieved, and therefore the galanthamine can be taken as a novel feed additive with an anti-inflammatory effect or an injection with an anti-inflammatory effect for injection operation.

The invention relates to a separation and purification method of mouse intestinal epithelium mucosa lamina propria dendritic cells, which comprises the following specific steps: (1) the acquisition of mixed cells; (2) the acquisition of individual karyocytes: preparing cells acquired after the digestion of collagenase into a suspension, slowly adding into a mouse lymphocyte separation liquid according to a volume ratio of 1:1, and centrifuging at 1800 rpm for 25 minutes; sucking the middle buffy coats, adding into 1-2 milliliters of MACS buffer, and centrifuging at 1200 rpm for 5 minutes; and removing the supernate, and suspending the cells again, wherein the MACS buffer is a PBS (phosphate buffer solution) containing 2mM mol/milliliter EDTA (ethylene diamine tetraacetic acid) and 0.5% FCS (fetal calf serum); and (3) the acquisition of intestinal epithelium mucosa lamina propria dendritic cells. By using the separation and purification method, a large number of high-purity and high-activity intestinal epithelium mucosa lamina propria dendritic cells can be conveniently, economically and efficiently acquired in short time; and the acquired cells keep a good antigen presentation capability under in vitro conditions, thereby providing favorable conditions for the in vitro simulation of in vivo antigen presenting cell induced lymphocyte differentiation.

The invention relates to application of bacteroides fragilis to preparation of an enhancing agent for enhancing an intestinal mucosal barrier function. According to a great quantity of experiments, the bacteroides fragilis has functions of repairing intestinal epithelium mucus barrier and reducing intestinal mucosal permeability and is capable of effectively enhancing the intestinal mucosal barrier function to protect human health.

The invention relates to application of patchoulicalcohol to preparing medicines for preventing and treating ulcerative colitis. The medicines comprise the patchoulicalcohol and medically acceptable excipients. The application has the advantages that the vitality of myeloperoxidase (MPO) which reflects the degrees of colitis diseases can be reduced by the patchoulicalcohol in the medicines, expression of tight junction proteins (TJs) and mucoproteins can be promoted, effects of protecting intestinal epithelium mucous membrane barriers can be realized, and obvious effects of preventing and treating the ulcerative colitis can be realized.

The invention relates to microbes and particularly relates to lactobacillus paracasei. The lactobacillus paracasei is characterized in that lactobacillus paracasei is lactobacillus paracasei CG-C1, the collection number is CGMCCNo. 12941, the collection date is September 8th, 2016, the collection unit is China General Microbiological Culture Collection Center, and the collection site is Instituteof Microbiology, Chinese Academy of Sciences, Beijing, China. The product is from the intestinal tract of a healthy centenarian. Proved by test, the lactobacillus paracasei CG-C1 is used for producingprobiotic fermented milk; the method is safe, low in risk, and easy in implementation, can ensure the quantity of strains and is lower in cost; compared with other methods, the method has obvious advantages. Therefore, the fermented milk product has the effects of regulating the intestinal flora, maintaining the balance of the intestinal microecological system, enhancing the expression of intestinal tight junction protein, improving the barrier function of the intestinal epithelium, reducing the level of cholesterol and relieving the problems of constipation and diarrhea.

The invention discloses a heat-stress-resistant premix used for laying hen feed. The heat-stress-resistant premix is prepared from the following components in percentage by weight: 5-8% of amino acid,10-15% of a vitamin mixture, 16-20% of a trace element mixture, 20-25% of a carrier, 30-35% of emulsified oil powder, 0.30-0.60% of salt and 0.10-0.80% of a spicate clerodendranthus herb extract, wherein trace elements in the trace element mixture comprise manganese, copper, zinc, iron, copper, zinc, iodine, selenium and chromium. The spicate clerodendranthus herb extract is adopted as a poultryadditive, the good antioxidant capability and intestinal epithelium protection effect are achieved, the egg yield of laying hens during heat stress is increased, and the egg quality is improved; the physiological index of the laying hens during heat stress is improved, and the laying hens are promoted to keep healthy; and the working procedure during heat stress is simplified, economic benefits are increased, and using is easy, convenient, safe and effective.

The present invention relates to a preparation method of an oral insulin preparation insulin-supporting carboxymethyl chitosan/chitosan nanometer preparation. The preparation method comprises: 1) forming core nanoparticles from carboxymethyl chitosan and insulin; 2) adding chitosan to a core nanometer suspension, and forming the outer layer of the nanoparticles on the surface of the core nanoparticles through the chitosan and the part of the carboxymethyl chitosan; and 3) stirring the obtained mixture until completely performing the cross-linking, carrying out high speed centrifugal separation, and carrying out freeze-drying to obtain the insulin-supporting carboxymethyl chitosan/chitosan nanoparticles. According to the present invention, the preparation conditions are mild, such that the insulin can be effectively protected from the influence caused by the gastrointestinal tract acid environment and the protease; the chitosan and the carboxymethyl chitosan can further promote the intestinal epithelium to absorb the insulin; and the results of the in vivo tests using diabetes rats as model animals show that the insulin-supporting carboxymethyl chitosan/chitosan nanometer preparation can effectively reduce the blood glucose of the rats.

A microfluidic device is directed to sustaining a complex microbial community in direct and indirect contact with living human intestinal cells in vitro. The device includes a first microchannel having cultured cells of a human intestinal epithelium and microbiota, the first microchannel further having a first level of oxygen. The device further includes a second microchannel having cultured cells of a vascular endothelium, the second microchannel further having a second level of oxygen. The device also includes a membrane located at an interface region between the first microchannel and the second microchannel, the membrane being composed of an oxygen-permeable material or further having pores via which oxygen flows between the first microchannel and the second microchannel to form a physiologically-relevant oxygen gradient.

The invention belongs to the field of biotechnology, and discloses a method for separating, identifying and preliminary screening of probiotic yak-derived lactic acid bacteria. The separation steps comprise: taking about 1 g of the middle portion of a manure sample, adding into a sterilized and refrigerated peptone buffer solution, sucking 1 mL of the manure supernatant under a sterile condition,inoculating into a MRS liquid culture medium, respectively carrying out aerobic culture and anaerobic culture for 24 h at a temperature of 37 DEG C, taking 200 [mu]l of the bacterial suspension, coating a MRS plate with the bacterial suspension, respectively carrying out aerobic culture and anaerobic culture for 24 h, selecting single suspected colony, inoculating into a corresponding plate culture medium, carrying out streak culture, respectively carrying out aerobic culture and anaerobic culture for 24 h at a temperature of 37 DEG C, re-selecting single colony, inoculating into a corresponding plate culture medium, respectively carrying out aerobic culture and anaerobic culture at a temperature of 37 DEG C, purifying twice, selecting single colony, inoculating into a corresponding slopeculture medium, respectively carrying out aerobic culture and anaerobic culture for 24 h at a temperature of 37 DEG C, and storing in a 4 DEG C a refrigerator so as to be spare. According to the present invention, the probiotic yak-derived lactic acid bacteria can protect the intestinal mucosa so as to reduce intestinal epithelium inflammation and diarrhea.

The invention belongs to the technical field of molecules and cellular biology, and particularly relates to a constructing method of a mouse intestinal epithelium pit cell line. The method comprises the steps that a single cell suspension of pit epithelium cells is prepared through a special separation method, cellular immortality is conducted after cell adherence. The form of intestinal epithelium primary cells is well maintained by the cell line, and high proliferation capability is achieved. Characteristic organ structures can be formed in three-dimensional culturing conditions, it is indicated by specific staining that cells which form the structure comprise multiple intestinal epithelium differentiated progeny. Pit cells of an established line can only grow in primary culturing conditions still, and the pit cells can be applied to the establishing of a mouse intestinal epithelium in vitro multi-dimensional study model which is used for studying intestinal physiologic functions andpathological mechanisms including infection, carcinogenesis and the like, and tools and platforms are provided for treatment targets and medicine screening and evaluating of intestinal diseases including intestinal cancer.

The invention belongs to the technical field of animal nutrition and intestinal health, and particularly discloses an application of glutamate binding peptide in preparation of a preparation for relieving intestinal injury induced by animal vomitoxin. The main components of the glutamate binding peptide are glutamic acid and glutamine, and the glutamate binding peptide can regulate up the Wnt/beta-catenin signal pathway protein level when the intestinal tract is damaged by vomitoxin, improve the proliferation and differentiation capability of intestinal stem cells and strengthen the intestinaltract barrier function, thereby promoting the regeneration of intestinal epithelium, maintaining the integrity of the intestinal tract and relieving the damage caused by the vomitoxin. The glutamatebinding peptide has an obvious effect of relieving mouse intestinal injury caused by the vomitoxin through a nutrition regulation and control means, and the addition of a small dose of the glutamate binding peptide can obtain a better effect and reduce the toxic reaction to the mouse intestinal tracts. Therefore, the glutamate binding peptide is not only suitable for preventing and controlling animal feed-derived diarrhea, but also provides a new way for developing a human intestinal tract health regulating agent.

Use of at least one protease inhibitor (I) to prepare a composition for preventative or curative treatment of intestinal disorders characterized by hyperalgesia. - An INDEPENDENT CLAIM is also included for a pharmaceutical product (A) containing at least one (I) and at least one other agent (II), i.e. an anticholinergic, prokinetic or antidiarrhea agent; laxative; modifier of motility or of viscero-sensitivity, for combined use, separately or sequentially. - ACTIVITY - Analgesic; Antiinflammatory. - MECHANISM OF ACTION - (I) control (reduce) the paracellular permeability of the intestinal epithelium, by controlling the light junctions, and associated pain. Proteases, produced by bacteria in the colon, activate receptors in the membrane of epithelial cells that modulate opening of these junctions, where opening is responsible for hyperalgesia. Mice were perfused, through the colon, with 250 mu l/hour of a solution of protease inhibitors, labeled with 51-chromium-EDTA. After 5 hours, the colons were removed and the amount of bound radioactivity measured as an indicator of paracellular permeability. For a control, retention of radioactivity was about 2.1%; compare about 1.1% following perfusion with a cocktail of protease inhibitors (or with serine protease or matrix metalloprotease inhibitors).

The invention relates to application of Metrnl in preventing and treating ulcerative colitis. According to the application, a DSS (Dextran Sulfate Sodium) induced ulcerative colitis model is established by using Metrnl intestinal epithelium specific knock-out mice and corresponding reference wild mice, and results show that the Metrnl intestinal epithelium specific knock-out mice are suffered fromulcerative colitis which is conspicuously more serious than that of the reference wild mice, the intestinal mucosa erosion degrees of the Metrnl intestinal epithelium specific knock-out mice are conspicuously higher than those of the reference wild mice, and a Metrnl protein can be used as a novel effective medicine for preventing and treating ulcerative colitis. The invention provides a novel method for preventing and treating ulcerative colitis, and in addition, since the Metrnl protein self is an endogenous protein of human bodies, the Metrnl protein has very small possible side effects onhuman bodies and is very high in security as a potential medicine.